Dr. Jonathan Kay of the University of Massachusetts Medical School told the 2018 Interdisciplinary Autoimmune Summit that biosimilar competition in Europe has reduced drug costs, made biosimilars more available and increased market share for some bio-originators. The European Union has approved 41 biosimilar drugs while the FDA has approved nine.